Antifungal drug fails to show promise in brain cancer trial
NCT ID NCT04869449
First seen Nov 18, 2025 · Last updated May 14, 2026 · Updated 20 times
Summary
This early-phase study aimed to see if ketoconazole, a drug used for fungal infections, could enter glioblastoma brain tumors in high enough amounts to stop cancer cells from dividing. Only one person took part before the study was stopped early. The main goal was to measure drug levels in the tumor, not to treat the disease directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
Conditions
Explore the condition pages connected to this study.